Abstract: BACKGROUND: Flow-mediated dilation (FMD) of human conduit arteries is, in part, related to shear stress-induced release of endothelium-derived nitric oxide (NO). However, NO synthase inhibitors do not completely abolish this FMD-response. Recently, a cytochrome P450 (CYP) epoxygenase of the 2C family was linked to NO-and prostacyclin-independent relaxation of conduit arteries. We therefore evaluated the contribution of CYP 2C9 to FMD in humans. METHODS AND RESULTS: FMD of the radial artery was determined in 12 healthy volunteers by high-resolution ultrasound and analyzed before and after intra-arterial infusion of sulfaphenazole, a specific CYP 2C9 inhibitor, L-NMMA (NO synthase inhibitor) and co-infusion of both. Endothelium-independent vasodilation was characterized after intraarterial infusion of SNP. FMD was reduced after sulfaphenazole (11.5+/-0.87% vs. 7.4+/-0.95%, p<0.01), after L-NMMA (6.0+/-0.71%; p<0.01), and after co-infusion 3.9+/-0.73% (p<0.05 vs. L-NMMA; p<0.01 vs. sulfaphenazole). Sulfaphenazole had no effect on endothelium-independent vasodilation. In patients with chronic heart failure, the portion of FMD blocked by sulfaphenazole was not affected. CYP 2C was detected by immunohistochemistry in radial artery samples obtained from patients undergoing coronary bypass surgery. CONCLUSIONS: FMD in human conductance arteries is reduced after inhibition of CYP 2C9, supporting the concept that CYP 2C metabolites contribute to endothelium-mediated vasodilation of peripheral conduit arteries in vivo. In patients with heart failure, the CYP-dependent FMD appears to be preserved. Background: Flow-mediated dilation (FMD) of human conduit arteries is, in part,
Introduction
Flow-mediated dilation of conductance arteries is a principle mechanism by which changes in flow affect vascular tone and vasodilation. Numerous experimental and, more recently, clinical studies have established that the shear-stress induced release of nitric oxide (NO) contributes to the flow-mediated vasodilation of arterial conductance vessels. However, we and others have noted that a residual response remains after blocking the production of NO and the generation of prostacyclin. [1] [2] [3] In fact, prolonged episodes of reactive hyperemia result in enhanced residual FMD that is not affected by NO synthase inhibitors. 3 Experimental studies have demonstrated that additional endothelium-derived factors can contribute to FMD in animals. Indeed, in some arteries an endothelium-derived hyperpolarizing factor (EDHF) has been implicated in this process and it has been suggested that the residual FMD observed after the NO synthase blockade can be attributed to an EDHF-mediated vasorelaxation. 4 It has previously been demonstrated that a cytochrome P450 epoxygenase of the 2C family (CYP 2C) expressed in the endothelium plays a crucial role in the generation of EDHF-mediated responses in porcine coronary arteries. 5 More recently, CYP 2C9 has been identified in the endothelium of human mammary arteries and has been shown to generate the vasodilator 11,12-epoxyeicosatrienoic acid (11, . 6 However, in addition to generating EETs, the CYP 2C epoxygenase can also generate oxygenderived free radicals which attenuate the bioavailability of NO. 6 Notably, this "EDHF synthase" can be efficiently and selectively inhibited by the sulfonamide sulfaphenazole both in animals and humans. 5, [7] [8] [9] The aim of the present study was to determine whether CYP 2C9 contributes to the flow-induced dilation of conduit arteries in humans and whether the contribution of the 4 enzyme to FMD is attenuated or exaggerated in disease states such as chronic heart failure. We therefore studied the effect of sulfaphenazole on FMD of the radial artery in healthy volunteers and patients with chronic heart failure.
Methods

Study population
The study protocol was approved by the Ethics Committee of the Medizinische Hochschule Hannover. Twelve young healthy volunteers, who gave their informed consent, were included and their baseline characteristics are outlined in table 1. All subjects were nonsmokers, normotensive, did not take any cardiac medication, and had normal serum cholesterol levels. Patients with chronic heart failure (NYHA functional class II and III) were also included in this study. The clinical characteristics of patients with chronic heart failure are depicted in table 2. The functional NYHA class was evaluated the day before FMD-measurement.
Measurement of FMD
Radial artery diameters were measured using a high-resolution ultrasound system (ASULAB) with a precision of ± 2.5 µm. This method is well established in our laboratory, has an excellent reproducibility and variability, as reported previously. was infused (4 mg/min for 5 minutes) intra-arterially (brachial artery), followed by intraarterial saline infusion during arterial occlusion and determination of FMD after release of arterial occlusion. It has been reported previously that administration of a similar dose of sulfaphenazole resulted in local plasma levels, high enough to effectively inhibit CYP 2C acitivity 10 . Next, N-monomethy-L-arginine (L-NMMA, Calbiochem, CN Biosciences, La Jolla, CA, USA; in saline 0.9 %) was infused intra-arterially (brachial artery) to inhibit the endothelial NO synthase (7 µmol/min for 5 minutes), FMD was determined after wrist arterial occlusion for 8 minutes. After again obtaining baseline levels, an intraarterial (brachial artery) co-infusion of sulfaphenazole and L-NMMA (doses as mentioned above, each 5 min) was performed and FMD was determined. Finally an intra-arterial (brachial artery) infusion of sodium-nitroprusside (SNP; Schwarz Pharma, Monheim, Germany; 9 µg/min for 5 minutes in saline 0.9 %) to assess endotheliumindependent vasodilatory capacity was performed.
All measurements were performed in a quiet room with an ambient temperature between 22° and 24° C. Alcohol and caffeine were prohibited within 12 hours of the study.
Immunhistochemistry
Radial artery specimens were obtained from patients who underwent coronary artery bypass graft surgery (n=6). Freshly isolated radial artery specimens were washed in ice cold PBS and immediately embedded in tissue freezing medium (Jung) and stored at -80°C. Frozen sections were fixed in phosphate-buffered formaldehyde solution (4%), permeabilized using Triton X-100 (0.2%) and blocked with bovine serum albumin 7 solution (3%) and horse serum (5%) in phosphate-buffered saline. CYP 2C was detected using a specific polyclonal CYP 2C antibody (kindly provided by Dr. E.
Morgan, Atlanta, GA) and ß-actin using a monoclonal antibody (Sigma). Preparations were then washed and incubated with fluorescent secondary antibodies (Alexa), mounted and images were acquired by laser scanning microscopy (LSM 510 meta, Carl
Zeiss, Jena, Germany).
Statistics
Data are expressed as the mean ± SEM and data were analyzed by ANOVA for repeated measures followed by Student Newman Keuls test. A value of p < 0.05 was considered to be statistically significant.
Results
Arterial blood pressure and heart rate did not change during the study protocol. The intra-arterial infusion of sulfaphenazole was well tolerated, and no side effects were observed. Radial arterial diameters are depicted in table 3 (healthy subjects) and table 4 (heart failure patients). No changes of the baseline diameter were observed after infusion of sulfaphenazole or L-NMMA. 
Effect of sulfaphenazole on FMD
Effect of Sulfaphenazole on endothelium-independent vasodilation
To determine whether the effect of sulfaphenazole is specific for endothelium-mediated vasodilation, we assessed the effect of sulfaphenazole on endothelium independent relaxation elicited to sodium nitroprusside (SNP). As shown in figure 2, sulfaphenazole had no effect on the SNP-induced, endothelium-independent vasodilation (FMD 19.6 + 1.87 % vs 20.2 + 2.16 %, p= n.s).
Effect of drugs infusions on reactive hyperemic blood flow
Blood flow before and after release of the cuff was assessed to ascertain whether or not the stimulus, i.e. the increase in flow, was similar during the different drug infusions.
Blood flow at rest was significantly reduced after sulfaphenazole infusion in healthy subjects (table 3) , however, neither of the compounds had a significant effect on reactive hyperemic blood flow, suggesting that the stimulus for flow-dependent dilation was similar in all groups. The results for radial artery blood flow are depicted in table 3 for healthy subjects and in table 4 for heart failure patients.
Effect of sulfaphenazole on FMD in patients with heart failure
When compared with responses observed in healthy volunteers, flow-mediated dilation was attenuated in patients with heart failure. Sulfaphenazole significantly reduced FMD in patients with heart failure (p<0.01), an effect that was similar to the observations in healthy volunteers. The co-infusion of L-NMMA and sulfaphenazole caused an additional reduction in FMD compared to the infusion of L-NMMA alone. Sulfaphenazole had no effect on the endothelium-independent vasodilation elicited by SNP in patients with heart failure (data not shown). To analyse the effect of sulfaphenazole in severe heart failure patients, subjects were divided in two groups. One group had a FMD lower 9 than the median (7.76%), the other group had a FMD greater than the median.
However, there was still a significant inhibition of FMD after infusion of sulfaphenazole in patients with a FMD below the median value (FMD control 5.7 + 0.49 %, FMD after sulfaphenazole infusion 3.4 + 0.72 %, p < 0.05).
Immunhistochemical detection of CYP 2C in radial arteries
In immunhistochemical studies, the expression of CYP 2C protein was detected in endothelial cells and in some samples in cells infiltrating the medial layer of the radial artery (figure 4), the vessel segment which was investigated in vivo by our echotracking device.
Discussion
The results of the present study demonstrate that FMD in human conductance arteries is substantially reduced after inhibition of CYP 2C9 supporting the concept that a factor generated by this enzyme contributes to flow-mediated, endothelium-dependent vasodilation of peripheral conduit arteries in vivo. In patients with heart failure, the CYPdependent FMD appears to be preserved. Importantly, the expression of CYP 2C was detected by immunhistochemistry in radial artery samples obtained from patients undergoing coronary bypass surgery, the same vascular bed in which FMDmeasurements were performed in the in vivo studies.
Recent studies by our group and others have shown that the dila tion of conduit arteries in response to reactive hyperemia is reduced by inhibitors of NO synthesis, suggesting an important role of NO in FMD [1] [2] [3] . However, several reports have indicated that FMD is a complex phenomenon involving the synthesis and release of more than one factor and that a substantial portion of the response may be independent of NO production 2, 3 .
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In both animals and humans, coronary FMD in response to prolonged hyperemia has previously been reported to be resistant to NO synthase inhibition.
9,11
Recently, Archer et al. responses in human conduit arteries, rather than in the forearm microcirculation.
In the latter vascular bed however, i.e. in the forearm microcirculation, an increase in the activity of a CYP 2C enzyme has been associated with a markedly different effect and Fichtlscherer et al. 9 reported that in patients with manifest coronary artery disease the inhibition of CYP 2C results in a marked improvement of the acetylcholinestimulated, endothelium-dependent and NO-mediated vasodilations. The latter effect was attributed to the inhibition of CYP 2C-derived reactive oxygen species which would be expected to react with NO and thus decrease its bioavailability. 8, 9 Similarly, in patients with hypertension there a pronounced effect of sulfaphenazole on the acetylcholine stimulated endothelium-dependent vasodilation has recently been observed. 13 In the present study we have characterized for the first time the effect of sulfaphenazole on the endothelium-dependent vasodilation in patients with chronic heart failure in a conductance artery. In patients with heart failure, sulfaphenazole had a similar effect on endothelium-dependent vasodilation as compared to healthy subjects, suggesting that the CYP2C response cannot compensate for impaired NOmediated vasodilation in patients with CHF.
A number of different factors and/or mechanisms have been proposed to underlie the EDHF phenomenon and compensate for the loss of NO by acting as a back up system to maintain FMD (for review see 15 ). The literature relating to the identity of putative EDHFs is highly confusing, perhaps more so since -in addition to the release of it is tempting to speculate that a CYP enzyme may underlie both responses.
As NO-mediated responses are attenuated in heart failure and physiologically relevant concentrations of NO attenuate CYP activity in healthy vessels 20, 21 , we expected the attenuated NO-dependent responses to be associated with an alleviation of the intrinsically inhibited EDHF response. However, rather than recording a more pronounced contribution of EDHF to FMD in patients with chronic heart failure we found that the inhibitory effects of sulfaphenazole on FMD were comparable in normal individuals and in patients with heart failure. At this point it is important to note that in previous studies have shown that NO-dependent FMD is impaired in patients with heart failure. 1, 2 However in the present investigation, the extent of blockade of FMD by L-NMMA was somewhat reduced as compared to our earlier studies 1,2 . Our patients were treated with ACE-inhibitors, statins and aldosterone inhibitors which, in contrast to our previous observations 1, 2 , have all been shown to improve endothelial function, at least partly, by reducing oxidative stress. [22] [23] [24] Drug treatment may even increase the expression of CYP 2C as nifedipine 25 , cerivastatin and fluvastatin Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure.
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